S
Simnova
Simnova Bio is a clinical stage biotechnology company focused on developing Cell Therapies to treat cancer
About Simnova
Simnova Biotherapeutics is a clinical-stage biotechnology company dedicated to developing advanced cell therapies for cancer treatment. Founded in 2019 as the cell therapy discovery arm of Simcere Pharmaceuticals in Cambridge, MA, Simnova became an independent entity in 2021 with operations in both China and the United States. The company focuses on creating best-in-class cell therapies, aiming to revolutionize cancer treatment through innovative biotechnological solutions.
Simnova Biotherapeutics primarily serves patients battling various forms of cancer, offering them cutting-edge therapeutic options that leverage the latest advancements in cell therapy. The company operates in the highly competitive biotechnology market, where it distinguishes itself through its strong research and development capabilities and strategic partnerships.
The business model of Simnova Biotherapeutics revolves around the development, clinical testing, and eventual commercialization of its cell therapy products. Revenue is generated through a combination of research grants, partnerships with pharmaceutical companies, and future sales of approved therapies. By focusing on both the U.S. and Chinese markets, Simnova aims to maximize its reach and impact in the global fight against cancer.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2019
- Headquarters
- China
- Open positions
- None listed
- Dealroom signal
- 20.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Aug 2026 | $55M | $220M | Youshan Capital · Yuanhe Holdings · FT Capital · Qianji Capital | ↗ |
| SERIES A✓Equity / VC | Mar 2024 | $28M | $110M | Youshan Capital · Yuanhe Yuandian · Pudao Capital · Guochuang Qinzhi | ↗ |
Growth signals
Latest recorded traffic for Simnova is 420 monthly website visits, up 23.5% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A8 investors entered at this stage
Youshan Capital- YYYuanhe Yuandian
- PCPudao Capital
- GQGuochuang Qinzhi
- FCFT Capital
- QCQianji Capital
- PCPudong Venture Capital
- YHYuanhe Holdings
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Simnova on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Simnova’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.